Country: South Korea

MEPSGEN is a biotechnology company that develops human microphysiological systems (MPS) also known as organ-on-a-chip and that employs the innovative on-chip products to predict drug toxicity and efficacy more accurately for the rapid and effective translation of new medicines to market. MEPS-X, the MPS product platform series of MEPSGEN, enables researchers to model human physiology and pathology of key organs at tissue levels. MEPS-TBC, one representative manufactured plastic chip, provides microfluidic spaces designed for modeling tissue-to-tissue barriers with high reproducibility. MEPS-BBB, a model of the human blood-brain barrier built on MEPS-TBC, has been being used by pharmaceutical companies to test drug permeation into the brain, receptor-mediated transcytosis of drug delivery systems, and immune cell trafficking at the BBB while monitoring the barrier function with TEER. MEPSGEN has the cryopreserved product of MEPS-BBB released for researchers to simply incubate the “ready-to-use” MEPS-BBB and test their drugs with no additional effort to build the model. With more MPS models for brain, liver, kidney, lung, and skin being developed by MEPSGEN, this cryopreserved MPS products will help bring the global market expansion of MPS models as a widely used alternative drug test tool to animal studies in near future. With the technology, MEPSGEN has nanomedicine pipelines targeting Alzheimer’s diseases and brain tumors. One representative nanomedicine MG-PE3 currently in the preclinical phase is a lipid nanoparticle that incorporates apoE for clearing amyloid with no side effect. MG-GTX13 is a nanomedicine that targets glioblastoma and other brain tumors. MEPSGEN also has developed a new microvortex device that can produce lipid nanoparticles (LNPs) encapsulating mRNAs. This technology will enable more effective incorporation of mRNA with greater encapsulation efficiency and higher productivity. | MEPSGEN, a biotech founded by YongTae Kim and Robert Langer in 2019, develops microengineered physiological systems so called organ-on-a-chip and uses the manufactured systems to study pathophysiological mechanisms of key diseases and screen new drug candidates for the treatment. With these studies supported by the technologies, the company has its own multiple new drug candidates, representative ones of which target Alzheimer’s and brain tumors. The company specializes in developing and producing a 3D cell culture Microphysiological System platform and in discovering new therapeutics using nanomedicine technology. The products and services include improved accuracy in evaluating new drug candidates and reducing cost and duration of the development. The company carries out fundamental biological research and drug candidate test in an environment equipped with an organ-level function of connected human tissues, rather than studying in a traditional in-vitro experimental model using 2D cell culture, thereby enabling researchers to further verify the findings in more pathophysiologically relevant environments. MEPSGEN is holding many patents, patents pending, and numerous IP licenses in the biotechnology field. For more information visit www.mepsgen.com | MEPSGEN is a biotechnology company that develops human microphysiological system as predictive models of human physiology, alongside unprecedented microfluidic modules — ranging from lab-scale nanoparticle synthesis to automated, large-scale GMP manufacturing — enabling the production of various types of nanoparticles with precisely defined properties and tunable scalability. This pioneering, technology-driven R&D is poised to play a transformative role in making drug development more efficient and scientifically grounded, ultimately contributing to better outcomes for patients suffering from some of the most difficult-to-treat diseases.